Target intelligence / Profile preview

Collagen type XIII alpha 1 chain (COL13A1)

Target
COL13A1
Molecular classification
Collagen (nonfibrillar, transmembranous), Type II transmembrane glycoprotein, Extracellular matrix protein
01

Overview

Collagen type XIII alpha 1 chain is a transmembranous, nonfibrillar collagen encoded by the COL13A1 gene in humans. Unlike most collagens, which are secreted into the extracellular matrix, collagen XIII embeds in the plasma membrane due to its transmembrane domain. Its function involves cell adhesion—both to the matrix and between cells—playing key roles in development, synaptic organization at neuromuscular junctions, and tissue integrity. It binds heparin, fibronectin, integrins (notably alpha 1), nidogen-2, and perlecan; it can be cleaved to release a soluble extracellular domain. Pathogenic variants cause congenital myasthenic syndromes by impairing neuromuscular junction function. The protein is broadly expressed in connective tissue-producing cells, muscle, placenta, and other tissues; alternative splicing yields multiple isoforms, some with tissue-specific roles.

Other names
Collagen alpha-1(XIII) chainCOL13A1Collagen, type XIII, alpha 1CMS19COLXIIIA1Collagen XIII alpha 1Collagen 13-alpha 1
02

Mechanism of action

No direct drugs or inhibitors are known; mechanism of action for potential therapeutic interventions would focus on altering cell-matrix adhesion, receptor clustering, or modulating interactions with integrins and extracellular matrix components

03

Biological functions

Cell-matrix adhesionCell-cell adhesionLinkage between muscle fiber and basement membraneEndochondral ossification (bone formation)Branching morphogenesis (lung development)Heparin bindingAcetylcholine receptor clustering (neuromuscular junction)
04

Disease associations

Congenital myasthenic syndromes (CMS19)Presynaptic congenital myasthenic syndromesMyasthenic syndrome, congenital, 19
05

Safety considerations

Targeting cell adhesion or neuromuscular junction function may risk muscular or developmental side effectsAlterations can affect tissue integrity and synaptic transmission, potentially impacting muscle strength and nerve signaling
06

Biomarkers

Mutations in COL13A1 serve as genetic biomarkers for congenital myasthenic syndromes (CMS19)Presence/abnormal expression in tissues may be indicative of cell adhesion disorders or related developmental abnormalities

Beyond the preview

Go deeper on Collagen type XIII alpha 1 chain (COL13A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collagen type XIII alpha 1 chain (COL13A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call